Abstract
The suggestion that prostaglandins may play an important role in immune response/tumor cell interactions is based upon several observations. First, a variety of prostaglandins are produced both by cells that are themselves active in the expression and regulation of immune response activity (1–4) as well as by a number of tumor targets (5,6). Second, the production of prostaglandins has been found to increase as a result of direct contact between effector lymphocytes and tumor targets (7). Third, prostaglandins at levels produced during these interactions have been shown to influence the ultimate expression in vitro of lymphocyte and macrophage cytotoxicity against tumor targets (8–12).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Tomar RH, Darrow TL, John PA: Response to and production of prostaglandin by murine thymus, spleen, bone marrow, and lymph node cells. Cell Immunol (60): 335, 1981.
Snider MW, Fertel RH, Zwilling BS: Prostaglandin regulation of macrophage function: effect of endogenous and exogenous prostaglandins. Cell Immunol (74): 234, 1982.
Koga Y, Taniguchi K, Kubo C, Nomoto K: Peritoneal adherent cells inhibit the generation of cytotoxic T-lymphocytes with prostaglandin-mediated system. Cell ImmunoL (66): 195, 1982.
Shimamura T, Hashimoto K, Sasaki S: Feedback suppression of the immune response in vivo. II. Involvement of prostaglandins in the generation of suppressor-inducer B lymphocytes. Cell Immunol (69): 192, 1982.
Karnali RA: Review: prostaglandins and cancer. Prostaglandins Med (5): 11, 1980.
Goodwin JS: Prostaglandin E and cancer growth potential for immunotherapy with prostaglandin synthetase inhibitors. IN: Hersh EM, Chirigos MA, Mastrangelo MJ (eds) Progress in Cancer Research and Therapy. Augmenting Agents in Cancer Therapy. Raven Press, New York, 1981, vol. 16, p 393.
Owen K, Gomolka D, Droller MJ: Lymphocyte-induced production of prostaglandin E2 by tumor cells in vitro: requirements for direct contact and lymphocyte viability. Cell Immunol (55): 428, 1980.
McCarthy ME, Zwilling BS: Differential effects of prostaglandine on the anti-tumor activity of normal and BCG-activated macrophages. Cell Immunol (60): 91, 1981.
Koren HS, Anderson SJ, Fischer DG, Copeland CS, Jensen PJ: Regulation of human natural killing. I. The role of monocytes, interferon, and prostaglandine. J Immunol (127): 2007, 1981.
Leung KH, Koren HS: Regulation of human natural killing. II. Protective effect of interferon on NK cells from suppression by PGE2. J Immunol (129): 1742, 1982.
Droller MJ, Lindgren JA, Claessen HE, Perlmann P: Production of prostaglandin E2 by bladder tumor cells in tissue culture and a possible mechanism of lymphocyte inhibition. Cell Immunol (47): 261, 1979.
Brunda MJ, Herberman RB, Holden HT: Inhibition of murine killer cell activity by prostaglandins. J Immunol (124): 2682, 1980.
Kendall RA, Tarean S: The dual effect of prostaglandin and ethanol on the natural killer cytolytic process: effector activation and NK cell-target cell conjugate lytic inhibition. J Immunol (125): 2770, 1980.
Drysdale BE, Shin HS: Activation of macrophages for tumor cell cytotoxicity: identification of indomethacin sensitive and insensitive pathways. J Immunol (127): 760, 1981.
Plescia OJ, Smith AH, Grimwich K: Subversion of the immune system by tumor cells and the role of prostaglandins. Proc Nat Acad Sci (72): 1848, 1975.
Heney CS, Bourne HR, Lichtenstein LM: The role of cyclic 3’5’ adenosine monophosphate in the specific cytolytic activity of lymphocytes. J Immunol (108): 1526, 1972.
Strom TB, Deisseroth A, Morganroth J, Carpenter CB, Merrill JP: Alteration of the cytotoxic action of sensitized lymphocytes by cholinergic agents and activators of adenylate cyclase. Proc Nat Acad Sci (69): 2995, 1972.
Goodwin JS: Prostaglandin and regulation of mitogenesis. Cell Immunol (52): 239, 1980.
Gordon D, Bray MA, Morley J: Control of lymphokine secretion by prostaglandins. Nature (262): 401, 1976.
Baker PE, Fahey JV, Munck A: Prostaglandin inhibition of T-cell proliferation is mediated at two levels. Cell Immunol (61): 52, 1981.
Droller MJ, Schneider MU, Perlmann P: A possible role of prostaglandins in the inhibition of natural and antibody-dependent cell-mediated cytotoxicity against tumor cells. Cell Immunol (39):165, m 1978.
Droller MJ, Perlmann P, Schneider MU: Enhancement of natural and antibody-dependent lymphocyte cytotoxicity by drugs which inhibit prostaglandin production by tumor target cells. Cell Immunol (39): 154, 1978.
Erturk E, Price JM, Morris JE, Cohen S, Leith BS, vonEsch AM, Crovetti AJ: The production of carcinoma of the urinary bladder in rats by feeding N-[4–1(5-nitro-2-furyl)-2-thiazolyll formamide. Cancer Res (27): 1998, 1967.
Owen K, Gomolka D, Droller MJ: Production of prostaglandin E2 by tumor cells in vitro. Cancer Res (40): 3167, 1980.
Droller MJ, Gomolka D: Enhancement of natural cytotoxicity in lymphocytes from animals with carcinogen-induced bladder cancer. J Urol (129): 625, 1983.
Droller MJ, Gomolka D: Interferon induction and prostaglandin synthetase inhibition in the in vitro and in vivo manipulation of immune response expression in an animal model of bladder cancer. Cell Immunol (72): 1, 1982.
Droller MJ, Gomolka D: Indomethacin and poly I:C in the inhibition of carcinogen-induced bladder cancer in an experimental animal model. Invest Urol, in press, 1984.
Droller MJ, Gomolka D: Inhibition of tumor growth in association with modifiction of in vivo immune response by indomethacin and polyinosinic:polycytidylic acid. Cancer Res (42): 5038, 1982.
Bennett A, Charlier EM, McDonald AM: Prostaglandins and breast cancer. Lancet (2): 624, 1977.
Bennett A, Carroll MA, Stamford IF: Prostaglandins and human lung carcinoma. Brit J Cancer (46): 888, 1982.
Khan O, Hensby CN, Williams G: Prostacyclin in prostatic cancer: a better marker than bone scan or serum acid phosphatase? Brit J Urol (54): 26, 1982.
Caro JF, Besarab A, Flynn JT: Prostaglandin E and hypercalcemia in breast carcinoma: only a tumor marker? A need for perspective. Amer J Med (66): 337, 1979.
Tanner NS, Stamford IF, Bennett A: Plasma prostaglandins in mucositis due to radiotherapy and chemotherapy for head and neck cancer. Brit J Cancer (43): 767, 1981.
Goodwin JS: Prostaglandin regulation of mitogenesis. Cell Immunol (52): 239, 1980.
Murray JL: Prostaglandin E2 modulation of human monocyte antibody-dependent cell-mediated cytotoxicity against human red blood cells. Cell Imnunol (71): 196, 1982.
Fischer A, Durandy A, Griscelli C: Role of prostaglandin E2 in the induction of non-specific T lymphocyte suppressor activity. J Immunol (126): 1452, 1981.
Goodwin JS, Webb DR: Regulation of the immune response by prostaglandins. Clin Immunol Imunopathol (15): 106, 1980.
Goodwin JS, Messner RP, Bankhurst AD: Prostaglandin-producing suppressor cells in Hodgkin’s Disease. New Engl J Med (297): 963, 1977.
Cameron DJ, O’Brien P: Relationship of the suppression of macrophage medicated tumor cytotoxicity in conjunction with secretion of prostaglandin from the macrophage of breast cancer patients. Int J Immunopharmacol (4): 445, 1982.
Panje WR, Maca R: Prostaglandin inhibitor sensitive suppressor cells: a product of survival in advanced head and neck cancer. International Symposium on Prostaglandins and Cancer, Washington, D.C., 1981.
Favolli C, Leport P, Jaffe BM, Santoro MG, Simmett T, Gobbo VD, Garaci E: The differential effects of PGE on the immune response in normal and immunosuppressed mice. Cell Immunol (72): 351, 1982.
Stringfellow DA: Prostaglandin restoration of the interferon response by hypoactive animals. Science (201): 376, 1978.
Taffet SM, Pace JL, Russell SW: Lymphokine maintains macrophage activation for tumor cell killing by interfering with the negative regulatory effect of prostaglandin E,. J Immunol (127): 121, 1981.
Tilden AB, Balch CM: A comparison of prostaglandin E2 effects on human suppressor cell function and on interleukin 2 function. J Immunol (129): 2469, 1982.
Wolf M, Droege W: Inhibition of cytotoxic responses by prostaglandin E2 in the presence of interleukin 2. Cell Immunol (72): 286, 1982.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1985 Martinus Nijhoff Publishing, Boston
About this chapter
Cite this chapter
Droller, M.J. (1985). Prostaglandins and Expression of Lymphocyte Cytotoxicity. In: Goodwin, J.S. (eds) Prostaglandins and Immunity. Prostaglandins, Leukotrienes, and Cancer, vol 4. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2603-8_2
Download citation
DOI: https://doi.org/10.1007/978-1-4613-2603-8_2
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-9630-0
Online ISBN: 978-1-4613-2603-8
eBook Packages: Springer Book Archive